Corporate Counsel: Pharma and Biotech Getting in the Post-grant IP Game

Originally Published in Corporate Counsel | January 26, 2015 | By Lisa Shuchman

biotechnology helix

By now it’s well-known that the post-grant proceedings implemented with the America Invents Act have have had a huge impact on the patent practices of companies in the technology and electronics fields. But the proceedings also have significantly altered the patent strategies used by in-house lawyers in the pharmaceutical and biotechnology sectors, according to a new survey.

See full article here.